# CRISPR Knockout: Mechanisms, Methods, and Applications ## Introduction to CRISPR Knockout ### What is a CRISPR Knockout? A CRISPR knockout is a permanent genetic modification that disrupts a target gene's coding sequence, rendering it non-functional. The term "knockout" distinguishes this approach from knockdown, which reduces gene expression transiently without altering the genomic DNA. In a CRISPR knockout, the endonuclease Cas9 (or an alternative enzyme such as Cas12a) is directed to a specific genomic locus by a short guide RNA. Upon binding, Cas9 generates a double-strand break (DSB) at the target site. The cell's endogenous DNA repair machinery then repairs this break, frequently introducing insertions or deletions (indels) that shift the reading frame or introduce premature stop codons. The result is a cell line or organism carrying a null allele at the targeted locus. The purpose of a CRISPR knockout is to abolish gene function permanently, enabling researchers to study the phenotypic consequences of gene loss. This is fundamentally different from other CRISPR applications. For example, [CRISPR Knock](/knowledge/molecular-biology/crispr-knock) refers to the broader family of CRISPR-based gene disruption techniques, while [CRISPR Cas 9](/knowledge/molecular-biology/crispr-cas-9) describes the specific enzyme most commonly used. CRISPR knockout is also distinct from CRISPR interference (CRISPRi), which uses a catalytically dead Cas9 (dCas9) fused to transcriptional repressors to silence gene expression without cutting DNA. ### CRISPR Knockout vs. CRISPR Interference The choice between CRISPR knockout and CRISPRi depends on the experimental question. CRISPR knockout produces complete, permanent gene loss, which is ideal for studying developmental processes, generating disease models, or conducting long-term phenotypic analyses. However, knockout is limited to genes that are non-essential for cell survival, because complete loss of an essential gene leads to cell death. CRISPRi, by contrast, allows reversible, titratable knockdown of gene expression. It is particularly useful for essential genes, where partial reduction of expression can reveal hypomorphic phenotypes. CRISPRi also avoids the confounding effects of off-target indels, because dCas9 does not cleave DNA. For high-throughput screens, CRISPRi offers a more uniform level of repression across a cell population, whereas CRISPR knockout can produce heterogeneous indels with variable effects on protein function. ## Mechanism of CRISPR Knockout ### Guide RNA Design and Target Selection The guide RNA (gRNA) is the specificity determinant of the CRISPR system. In the most common format, a single guide RNA (sgRNA) combines a CRISPR RNA (crRNA) that contains the target-specific spacer sequence with a trans-activating crRNA (tracrRNA) that is required for Cas9 loading. The spacer is typically 20 nucleotides long and must be complementary to the target genomic sequence. However, the target sequence alone is not sufficient for Cas9 binding; the enzyme also requires a protospacer adjacent motif (PAM) immediately downstream of the target site. For *Streptococcus pyogenes* Cas9 (SpCas9), the PAM is 5′-NGG-3′. The PAM is essential for initial DNA unwinding and R-loop formation; without it, Cas9 cannot engage the DNA. Target selection begins with identifying all PAM-adjacent sequences in the gene of interest. For a knockout, the gRNA should target the earliest possible exon that is common to all transcript isoforms, ideally within the first 5% of the coding sequence. This maximizes the chance that the resulting indel produces a truncated protein lacking functional domains. Targeting the 5′ end also reduces the likelihood of nonsense-mediated decay evasion, where a premature stop codon in the last exon fails to trigger mRNA degradation. For genes with multiple isoforms, choose an exon shared by all variants, or design multiple gRNAs targeting different exons. ### Cas9-Mediated Double-Strand Break Once the sgRNA and Cas9 form a ribonucleoprotein complex, the complex scans the genome for PAM sequences. Binding to a PAM triggers local DNA melting, allowing the sgRNA spacer to base-pair with the complementary strand. If the 20-nucleotide spacer matches the target perfectly, Cas9 undergoes a conformational change that activates its two nuclease domains: the HNH domain cleaves the strand complementary to the sgRNA, and the RuvC domain cleaves the non-complementary strand. The result is a blunt DSB located 3 nucleotides upstream of the PAM. The efficiency of cleavage depends on the stability of the RNA-DNA hybrid. Mismatches in the "seed region" (the 8–12 nucleotides proximal to the PAM) severely impair cleavage, while mismatches in the distal region are more tolerated. This tolerance is the basis for off-target activity, where Cas9 cleaves sites with partial homology to the sgRNA. The DSB is generated within milliseconds of stable R-loop formation, and the enzyme remains bound to the DNA ends after cleavage, which may influence the subsequent repair pathway choice. ### DNA Repair: NHEJ and HDR The DSB is resolved by one of two major repair pathways. Non-homologous end joining (NHEJ) is the dominant pathway in most cell types and is active throughout the cell cycle. NHEJ directly ligates the broken DNA ends, often with the introduction of small insertions or deletions. These indels are stochastic; their size and position vary between individual repair events. When an indel occurs within the coding sequence and its length is not a multiple of three, it causes a [frameshift mutation](/knowledge/molecular-biology/frameshift-mutation). This typically introduces a premature stop codon downstream of the lesion, leading to a truncated protein or nonsense-mediated decay of the mRNA. Even in-frame indels can disrupt function if they delete critical amino acid residues or protein domains. Homology-directed repair (HDR) is the alternative pathway, but it is only active in the S and G2 phases of the cell cycle. HDR uses a homologous DNA template to repair the break with high fidelity. In the context of CRISPR knockout, HDR is not typically used to create null alleles; instead, it is used to introduce precise edits such as point mutations or reporter gene insertions. For a simple knockout, NHEJ is the desired outcome. However, HDR can be exploited to insert a stop codon or a fluorescent marker into the target locus, creating a more defined null allele. The efficiency of HDR is generally low (1–10% in most cell lines) compared to NHEJ, and it requires the co-delivery of a repair template, either as a single-stranded oligodeoxynucleotide (ssODN) or a plasmid donor. ## Designing Guide RNAs for Efficient Knockout ### PAM Sequence Requirements The PAM is the first constraint in gRNA design. For SpCas9, the NGG PAM occurs on average once every 8 base pairs in the human genome, providing ample target sites. However, not all NGG sites are equally accessible; [chromatin structure](/knowledge/molecular-biology/chromatin-structure) can occlude Cas9 binding. Heterochromatic regions and nucleosome-bound DNA are less accessible than open euchromatin. Several algorithms incorporate chromatin accessibility data, such as DNase-seq or ATAC-seq signals, to predict gRNA efficacy. For genomes with low GC content, the NGG PAM may be limiting, and alternative Cas9 orthologs with different PAM requirements can be used. For example, *Staphylococcus aureus* Cas9 (SaCas9) recognizes a longer NNGRRT PAM, while Cas12a (Cpf1) recognizes a T-rich PAM (TTTV) and generates staggered cuts with 5′ overhangs. The choice of enzyme should be guided by the PAM availability in the target region. ### On-Target Scoring Algorithms Several computational tools predict gRNA on-target activity. The most widely used are the Doench et al. scoring rules, which were derived from high-throughput screens measuring the depletion of gRNAs targeting essential genes. These rules consider sequence features such as the GC content of the spacer, the presence of specific nucleotides at positions 20 and 21 (adjacent to the PAM), and the thermodynamic stability of the RNA-DNA duplex. A commonly used threshold is a Doench score above 0.5 for the "Azimuth" algorithm, which predicts a high probability of functional knockout. More recent tools, such as CRISPRscan and DeepCRISPR, use machine learning approaches trained on large datasets. It is advisable to design at least three gRNAs per target gene and empirically test their activity, because computational predictions are not perfectly accurate. ### Minimizing Off-Target Effects Off-target cleavage is a major concern in CRISPR knockout experiments, as it can produce unintended mutations that confound phenotypic analysis. The most important determinant of off-target activity is the sequence similarity between the sgRNA spacer and other genomic loci. Mismatches in the seed region are poorly tolerated, but mismatches in the distal region, especially when clustered, can still permit cleavage. The PAM-proximal region (positions 1–12 from the PAM) is the most critical for specificity. To minimize off-target effects, several strategies are available. First, use a gRNA design tool that reports off-target scores, such as the MIT specificity score or the CFD (cutting frequency determination) score. A CFD score above 0.2 is generally considered acceptable, but lower is better. Second, consider using a high-fidelity Cas9 variant, such as SpCas9-HF1 or eSpCas9(1.1), which contain mutations that reduce non-specific DNA contacts. These variants maintain on-target activity while dramatically reducing off-target cleavage. Third, use truncated gRNAs (17–18 nucleotides) that retain on-target activity but have reduced tolerance for mismatches. Finally, for applications where off-target effects are unacceptable, such as therapeutic development, use paired nickases (Cas9 D10A mutant) that generate single-strand nicks; two nickases targeting opposite strands create a DSB only when both gRNAs bind in close proximity, effectively doubling the specificity requirement. For a detailed discussion of these issues, see [CRISPR Off Target Effects](/knowledge/molecular-biology/crispr-off-target-effects). ## Delivery Methods for CRISPR Knockout ### Plasmid-Based Delivery Plasmid transfection is the most straightforward method for delivering CRISPR components. A single plasmid can encode both the sgRNA (under a U6 promoter) and Cas9 (under a constitutive promoter such as CMV or EF1α). Alternatively, Cas9 and sgRNA can be on separate plasmids. The advantages of plasmid delivery are low cost, ease of cloning, and the ability to include selectable markers such as puromycin resistance for enrichment of transfected cells. The disadvantages include the risk of random genomic integration of the plasmid backbone, sustained expression of Cas9 that increases off-target effects, and lower delivery efficiency in primary cells. For adherent cell lines such as HEK293T or HeLa, Lipofectamine 3000 or similar cationic lipid reagents are commonly used. A typical protocol uses 1–2 μg of plasmid DNA per well of a 6-well plate, with transfection efficiencies of 50–90% depending on the cell line. For cells that are difficult to transfect, such as primary neurons or T cells, plasmid delivery is often inefficient, and alternative methods should be considered. ### Ribonucleoprotein (RNP) Delivery RNP delivery involves pre-assembling the Cas9 protein with the sgRNA *in vitro* and then delivering the complex into cells. This approach has several advantages. First, the RNP is active immediately upon delivery, eliminating the lag time associated with [transcription and translation](/knowledge/molecular-biology/transcription-translation) of plasmid-encoded Cas9. Second, the RNP is degraded within 24–72 hours, reducing off-target effects and minimizing the risk of integration. Third, RNP delivery does not require cloning, making it faster and more flexible. The main disadvantage is the cost of recombinant Cas9 protein and the need for electroporation or microinjection for efficient delivery. For RNP electroporation, a typical protocol uses 1–5 μg of Cas9 protein complexed with 0.5–2 μg of sgRNA in a 10 μL reaction. The complex is formed by incubating Cas9 and sgRNA at room temperature for 10 minutes. Electroporation parameters vary by cell type; for Jurkat T cells, a Lonza 4D-Nucleofector with program CM-138 is commonly used, achieving >90% delivery efficiency. For primary cells, the Neon Transfection System (Thermo Fisher) with a 10 μL tip and a pulse of 1400 V, 20 ms, 2 pulses is a reasonable starting point. ### Viral Delivery (Lentivirus, AAV) Viral vectors enable delivery to cells that are refractory to transfection or electroporation, and they allow stable integration or long-term expression. Lentiviral vectors are the most common choice for CRISPR knockout in mammalian cells. A typical lentiviral construct (e.g., lentiCRISPRv2) encodes Cas9, the sgRNA, and a puromycin resistance gene. Lentivirus is produced by co-transfecting HEK293T cells with the transfer plasmid, a packaging plasmid (psPAX2), and an envelope plasmid (pMD2.G) at a ratio of 4:3:1 using a calcium phosphate or lipid transfection method. Viral supernatant is harvested 48–72 hours post-transfection, filtered through a 0.45 μm filter, and used to transduce target cells. For most cell lines, a multiplicity of infection (MOI) of 0.3–0.5 is used to ensure that most cells receive a single viral integration, reducing the chance of multiple gRNA integrations. Adeno-associated virus (AAV) is an alternative for *in vivo* delivery, but its small packaging capacity (~4.7 kb) is a limitation. This constraint requires the use of a smaller Cas9 ortholog such as SaCas9, which is ~3.2 kb, leaving room for a sgRNA and a minimal promoter. AAV is particularly useful for delivery to non-dividing cells such as neurons or hepatocytes, where lentiviral integration is less efficient. However, AAV can persist as episomes and may be diluted out in dividing cells, making it less suitable for stable knockout in proliferating populations. ## Validating CRISPR Knockout Efficiency ### Genotypic Validation: T7E1 and Sequencing The first step in validating a CRISPR knockout is to confirm that indels were introduced at the target locus. The T7 endonuclease I (T7E1) assay is a rapid and inexpensive method. Genomic DNA is extracted from the edited cell population, and the target region is amplified by PCR using primers that flank the cut site. The PCR product is denatured and re-annealed, allowing heteroduplexes to form between wild-type and mutant strands. T7E1 cleaves at mismatched sites in these heteroduplexes, producing smaller fragments that can be resolved by agarose gel electrophoresis. The fraction of cleaved DNA provides an estimate of editing efficiency. A typical reaction uses 200–500 ng of PCR product, 10 units of T7E1, and incubation at 37°C for 15–30 minutes in NEBuffer 2. For precise quantification, Sanger sequencing of the PCR product followed by decomposition analysis with tools such as TIDE (Tracking of Indels by DEcomposition) or ICE (Inference of CRISPR Edits) is recommended. These tools compare the sequencing chromatogram of the edited sample to that of a control and estimate the frequency and types of indels. For clonal cell lines, individual clones should be expanded and sequenced to confirm the presence of biallelic frameshift mutations. For high-throughput validation, next-generation sequencing (amplicon-seq) can quantify editing efficiency across multiple loci simultaneously. ### Phenotypic Validation: qPCR and Western Blot Genotypic validation confirms that the DNA was edited, but it does not guarantee that protein function is abolished. Some indels produce in-frame deletions that retain partial protein function, and some frameshift mutations may not trigger nonsense-mediated decay if the premature stop codon is in the last exon. Therefore, phenotypic validation is essential. At the RNA level, quantitative PCR (qPCR) can measure mRNA levels. If the [frameshift mutation](/knowledge/molecular-biology/frameshift-mutation) triggers nonsense-mediated decay, mRNA levels will be reduced. However, if the mutant mRNA is stable, qPCR will not distinguish between wild-type and mutant transcripts. For this reason, qPCR primers should be designed to span the cut site, so that amplification is disrupted by the indel. A typical qPCR reaction uses 10 ng of cDNA, 200 nM forward and reverse primers, and SYBR Green master mix, run for 40 cycles with an annealing temperature of 60°C. Relative expression is calculated using the ΔΔCt method with a housekeeping gene such as GAPDH or ACTB. At the protein level, Western blot is the gold standard. Use an antibody that recognizes an epitope N-terminal to the cut site; if the cut site is in the first exon, most antibodies will fail to detect the truncated protein. A loading control such as β-actin or tubulin is essential. For a complete knockout, no band should be visible at the expected molecular weight. If a truncated band is observed, the gRNA may have produced an in-frame deletion, and a different gRNA targeting a more 5′ exon should be tested. Flow cytometry can also be used if the target protein is surface-expressed and a fluorescent antibody is available. ## Applications of CRISPR Knockout ### Gene Function Studies The most fundamental application of CRISPR knockout is the elucidation of gene function. By generating a null allele, researchers can observe the phenotypic consequences of gene loss in a controlled system. For example, knocking out *TP53* in human cell lines recapitulates the loss of cell cycle checkpoint control and resistance to apoptosis, confirming its role as a tumor suppressor. In organoids or animal models, knockout of genes such as *APC* or *KRAS* can drive tumorigenesis, providing models for colorectal cancer. CRISPR knockout is also used to validate candidate genes identified by genome-wide association studies (GWAS); a knockout that phenocopies the disease-associated variant provides strong evidence of causality. ### Disease Modeling CRISPR knockout enables the creation of cellular and animal models of human genetic diseases. For recessive disorders, biallelic knockout of the disease gene recapitulates the null phenotype. For example, knockout of *CFTR* in intestinal organoids models cystic fibrosis, and knockout of *DMD* in myoblasts models Duchenne muscular dystrophy. These models are valuable for studying disease mechanisms and for testing therapeutic interventions. In mice, CRISPR knockout can be achieved by injecting Cas9 and sgRNA into zygotes, generating germline-transmissible mutations. This approach has been used to create models of neurodegenerative diseases, cardiovascular disorders, and cancer. The speed and efficiency of CRISPR knockout have largely replaced traditional [homologous recombination](/knowledge/molecular-biology/homologous-recombination) in embryonic stem cells for many applications. For more on the therapeutic potential of these approaches, see [CRISPR in Medicine](/knowledge/molecular-biology/crispr-in-medicine). ### High-Throughput Genetic Screens CRISPR knockout is uniquely suited for high-throughput [functional genomics](/blog/guides/functional-genomics) screens. Pooled libraries of sgRNAs targeting thousands of genes can be delivered to a cell population via lentiviral transduction. Cells are then subjected to a selective pressure, such as a drug, toxin, or growth condition. sgRNAs that target genes required for survival under the selective condition will be depleted from the population, while sgRNAs targeting genes that suppress survival will be enriched. The relative abundance of each sgRNA is quantified by next-generation sequencing of the integrated sgRNA sequences. This approach has identified genes involved in drug resistance, viral infection, and cancer cell fitness. For example, a genome-wide CRISPR screen in chronic myeloid leukemia cells identified *BCR-ABL1* fusion-independent mechanisms of imatinib resistance. The design and analysis of such screens are covered in detail in [CRISPR Screening](/knowledge/molecular-biology/crispr-screening). ## Common Pitfalls and Troubleshooting ### Off-Target Effects Off-target mutations are a persistent concern. Even with high-fidelity Cas9 variants and careful gRNA design, off-target cleavage can occur at low frequency. The consequences are especially problematic in phenotypic screens, where off-target mutations can produce false positives. To mitigate this risk, use at least two independent gRNAs targeting the same gene and confirm that the phenotype is consistent. If possible, perform a rescue experiment by expressing a wild-type copy of the gene that is resistant to the gRNA (by introducing silent mutations in the gRNA binding site). For whole-genome off-target detection, methods such as GUIDE-seq or CIRCLE-seq can identify off-target sites empirically. If off-target effects are detected, switch to a high-fidelity Cas9 or use paired nickases. ### Incomplete Knockout and Mosaicism In polyclonal cell populations, editing efficiency is rarely 100%. Some cells will remain wild-type, and others may carry in-frame indels that preserve protein function. This heterogeneity can mask phenotypes. The solution is to generate clonal cell lines by single-cell sorting or limiting dilution. After expansion, each clone should be genotyped by Sanger sequencing and validated by Western blot. In animal models, mosaicism arises because Cas9 continues to edit cells after the zygote stage, producing a mixture of edited and unedited cells. To reduce mosaicism, deliver the RNP complex directly into the zygote and screen founder animals for germline transmission of the mutation. ### Cell Toxicity and Delivery Issues Cas9 expression can be toxic to some cell types, particularly primary cells and stem cells. This toxicity is often due to off-target cleavage or to the [DNA damage response](/knowledge/molecular-biology/dna-damage-response) triggered by DSBs. If cell death is observed, reduce the amount of Cas9 delivered, use a high-fidelity variant, or switch to RNP delivery to limit the duration of Cas9 activity. Delivery efficiency can also be a bottleneck. If transfection efficiency is low, consider using lentiviral transduction or electroporation. For difficult-to-transfect cells, optimize the electroporation buffer and pulse conditions, and test different cell densities. If the target gene is essential for cell survival, CRISPR knockout will result in cell death, and no viable clones will be obtained. In this case, use CRISPRi for partial knockdown or generate a conditional knockout using a drug-inducible Cas9 (e.g., doxycycline-inducible) or a Cre-loxP system. ## Summary and Best Practices A successful CRISPR knockout experiment requires careful attention to each step of the workflow. The following best practices will maximize the likelihood of obtaining a clean, functional knockout: 1. **Design multiple gRNAs** targeting the earliest shared exon, and use a scoring algorithm to select those with high on-target and low off-target scores. 2. **Choose the appropriate delivery method** based on the cell type and experimental goals. RNP delivery is preferred for primary cells and for minimizing off-target effects; lentiviral delivery is best for stable expression and high-throughput screens. 3. **Validate at both the DNA and protein levels.** T7E1 or sequencing confirms editing, but Western blot is essential to confirm loss of protein function. 4. **Generate clonal cell lines** for phenotypic studies to avoid confounding effects from unedited cells. 5. **Use multiple gRNAs and perform rescue experiments** to confirm that observed phenotypes are due to on-target knockout. 6. **Consider the possibility of essential genes** and use alternative approaches such as CRISPRi if knockout is lethal. 7. **Document all gRNA sequences and editing outcomes** for reproducibility and for compliance with reporting standards. ## Frequently Asked Questions ### What is a CRISPR knockout? A CRISPR knockout is a permanent genetic modification that disrupts a target gene's coding sequence, rendering it non-functional. It is achieved by using a guide RNA to direct the Cas9 nuclease to a specific genomic locus, where it creates a double-strand break. The cell's DNA repair machinery then introduces insertions or deletions that typically cause a frameshift mutation and loss of protein function. ### How does CRISPR knockout work? CRISPR knockout works by exploiting the cell's natural DNA repair pathways. Cas9, guided by a sgRNA, binds to a target sequence adjacent to a PAM motif and generates a double-strand break. The break is repaired by non-homologous end joining, which frequently introduces indels. If the indel causes a frameshift, a premature stop codon is introduced, leading to a truncated protein or degradation of the mRNA. ### What is the CRISPR knockout protocol? A typical CRISPR knockout protocol involves: (1) designing and cloning a sgRNA into a Cas9 expression vector, (2) delivering the construct into cells via transfection, electroporation, or viral transduction, (3) selecting or enriching for edited cells, (4) validating editing by T7E1 assay or sequencing, and (5) confirming loss of protein function by Western blot. For RNP delivery, the Cas9 protein and sgRNA are pre-complexed and delivered directly. ### What are the applications of CRISPR knockout? CRISPR knockout is used for gene function studies, disease modeling, drug target discovery, and high-throughput genetic screens. It enables the creation of null alleles in cell lines and animal models, facilitating the study of gene function in development, disease, and therapy response. ### How do you validate a CRISPR knockout? Validation is performed at multiple levels. Genotypic validation uses T7E1 assay, Sanger sequencing with TIDE/ICE analysis, or next-generation sequencing to confirm indels. Phenotypic validation uses qPCR to measure mRNA levels and Western blot to confirm loss of protein. For clonal lines, sequencing of individual clones confirms biallelic frameshift mutations. ### What is the difference between CRISPR knockout and knockdown? CRISPR knockout permanently disrupts the genomic DNA, leading to complete loss of gene function. Knockdown, such as RNA interference (RNAi) or CRISPRi, transiently reduces gene expression without altering the DNA sequence. Knockout is irreversible and complete, while knockdown is reversible and can be titrated. Knockout is preferred for studying complete loss-of-function phenotypes, while knockdown is useful for essential genes or for studying dosage effects. ## Key Takeaways - CRISPR knockout uses Cas9 and a guide RNA to create a double-strand break, which is repaired by NHEJ to introduce frameshift mutations and permanently disrupt gene function. - Guide RNA design is critical: target the earliest shared exon, use a PAM-compatible sequence, and select gRNAs with high on-target and low off-target scores. - Delivery methods include plasmid transfection, RNP electroporation, and viral transduction; RNP delivery minimizes off-target effects and is preferred for primary cells. - Validation requires both genotypic (T7E1, sequencing) and phenotypic (qPCR, Western blot) confirmation to ensure complete loss of protein function. - CRISPR knockout is widely used for gene function studies, disease modeling, and high-throughput genetic screens, but it is not suitable for essential genes. - Common pitfalls include off-target effects, incomplete knockout, and cell toxicity; these can be mitigated with high-fidelity Cas9 variants, clonal selection, and careful optimization of delivery conditions. - Always use multiple gRNAs and perform rescue experiments to confirm that phenotypes are due to on-target knockout. ## Further Reading - Hart T et al. *Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens*. G3 (Bethesda, Md.). 2017. [PubMed 28655737](https://doi.org/10.1534/g3.117.041277) - Ueki H et al. *A CRISPR knockout mouse library for [functional genomics](/blog/guides/functional-genomics) in influenza research*. Cell. 2026. [PubMed 42302780](https://doi.org/10.1016/j.cell.2026.05.032) - Cheng KW et al. *Replicon-based genome-wide CRISPR knockout screening for the identification of host factors involved in viral replication*. Nature communications. 2025. [PubMed 41372121](https://doi.org/10.1038/s41467-025-65979-3) - Shalem O et al. *Genome-scale CRISPR-Cas9 knockout screening in human cells*. Science (New York, N.Y.). 2014. [PubMed 24336571](https://doi.org/10.1126/science.1247005) - Li Y et al. *Targeted CRISPR activation and knockout screenings identify novel doxorubicin transporters*. Cellular oncology (Dordrecht, Netherlands). 2023. [PubMed 37523060](https://doi.org/10.1007/s13402-023-00847-0) - Yin E, Esbin MN. *Optimized CRISPR-based knockout in BeWo cells*. Placenta. 2025. [PubMed 38997889](https://doi.org/10.1016/j.placenta.2024.07.005) ## Related Topics - [Zinc Finger Nuclease](/knowledge/molecular-biology/zinc-finger-nuclease) - [CRISPR Problems and Alternatives](/knowledge/molecular-biology/crispr-problems-and-alternatives) - [CRISPR Ethics](/knowledge/molecular-biology/crispr-ethics) - [CRISPR Delivery](/knowledge/molecular-biology/crispr-delivery)
## Related Clinical & Scientific Guides * [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway) * [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor) * [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)